(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.31%) $82.75
(6.34%) $2.05
(0.05%) $2 348.30
(-0.21%) $27.48
(3.91%) $958.15
(-0.22%) $0.933
(-0.33%) $10.99
(-0.55%) $0.796
(1.66%) $93.40
0.90% $ 1.120
Live Chart Being Loaded With Signals
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system...
Stats | |
---|---|
Tagesvolumen | 25 396.00 |
Durchschnittsvolumen | 132 512 |
Marktkapitalisierung | 42.70M |
EPS | $0 ( 2024-04-03 ) |
Nächstes Ertragsdatum | ( $-0.510 ) 2024-05-09 |
Last Dividend | $0.0900 ( 2014-08-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.610 |
ATR14 | $0.0130 (1.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Yonehiro Grant | Buy | 235 000 | Stock Option (Right to Buy) |
2024-03-04 | Perez Edith A. | Buy | 235 000 | Stock Option (Right to Buy) |
2024-03-04 | Schatzman Randall C | Buy | 654 000 | Stock Option (Right to Buy) |
2024-03-04 | Quinn William P. | Buy | 235 000 | Stock Option (Right to Buy) |
2023-12-31 | Yonehiro Grant | Buy | 0 |
INSIDER POWER |
---|
72.73 |
Last 93 transactions |
Buy: 5 349 325 | Sell: 1 125 168 |
Volumen Korrelation
Bolt Biotherapeutics, Korrelation
10 Am meisten positiv korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Bolt Biotherapeutics, Korrelation - Währung/Rohstoff
Bolt Biotherapeutics, Finanzdaten
Annual | 2023 |
Umsatz: | $7.88M |
Bruttogewinn: | $5.99M (76.08 %) |
EPS: | $-1.830 |
FY | 2023 |
Umsatz: | $7.88M |
Bruttogewinn: | $5.99M (76.08 %) |
EPS: | $-1.830 |
FY | 2022 |
Umsatz: | $5.73M |
Bruttogewinn: | $838 000 (14.63 %) |
EPS: | $-2.30 |
FY | 2021 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-2.97 |
Financial Reports:
No articles found.
Bolt Biotherapeutics, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0500 | 2012-03-06 |
Last Dividend | $0.0900 | 2014-08-29 |
Next Dividend | $0 | N/A |
Payout Date | 2014-10-02 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $0.830 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.61 | -- |
Div. Sustainability Score | 0.326 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -8.60 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.424 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.501 | 1.500 | -6.68 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.16 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.06 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.528 | 1.500 | 8.18 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.127 | -1.500 | 7.89 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 53.10 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.832 | 2.00 | -0.611 | -1.222 | [0 - 30] |
freeCashFlowPerShareTTM | -1.838 | 2.00 | -0.919 | -1.838 | [0 - 20] |
debtEquityRatioTTM | 0.179 | -1.500 | 9.28 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.577 | 1.000 | 3.72 | 3.72 | [0.2 - 0.8] |
operatingProfitMarginTTM | -9.67 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -3.44 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0493 | 0.800 | -3.00 | -2.40 | [0.5 - 2] |
Total Score | 0.326 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.622 | 1.000 | -0.164 | 0 | [1 - 100] |
returnOnEquityTTM | -0.501 | 2.50 | -4.29 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.838 | 2.00 | -0.613 | -1.838 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.832 | 2.00 | -0.611 | -1.222 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00463 | 1.500 | -3.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -8.83 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.76 |
Bolt Biotherapeutics,
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.